## Overview
Depression — clinically termed **major depressive disorder (MDD)** and coded as **ICD-10 F32** for a single depressive episode — is a common, serious, and treatable mood disorder characterized by persistent feelings of sadness, emptiness, or hopelessness, accompanied by a loss of interest or pleasure in activities that were once enjoyable. It affects how a person thinks, feels, and handles daily activities such as sleeping, eating, and working.
Depression is one of the leading causes of disability worldwide. According to the Global Burden of Disease Study 2019, depressive disorders affected an estimated 280 million people globally, making it the second-largest contributor to years lived with disability [1]. In the United States alone, the National Institute of Mental Health (NIMH) estimates that approximately 8.3% of adults experienced at least one major depressive episode in 2021.
People search for information about depression for many reasons: they may be experiencing persistent low mood and wondering if it qualifies as clinical depression, they may be seeking self-help strategies, or they may want to understand treatment options before visiting a healthcare provider. Whatever the reason, understanding depression — its causes, warning signs, and evidence-based treatments — is a crucial step toward recovery.
A diagnosis of MDD generally requires at least **five of nine core symptoms** persisting for two or more weeks, with at least one being depressed mood or loss of interest (anhedonia). These nine symptoms include depressed mood, anhedonia, significant weight or appetite change, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness or excessive guilt, difficulty concentrating, and recurrent thoughts of death or suicide [2].
It is important to emphasize that depression is not a sign of personal weakness or a condition one can simply "snap out of." It is a complex medical illness with biological, psychological, and social dimensions that generally responds well to appropriate treatment.
---
## Common Causes
Depression rarely has a single cause. It typically arises from an interaction of genetic vulnerability, neurobiological changes, psychological factors, and environmental stressors. Below are the most commonly recognized contributing factors, ranked approximately by how frequently they play a role in clinical presentations.
### 1. Neurochemical Imbalance and Neurotransmitter Dysfunction
The monoamine hypothesis — the most established neurobiological model — posits that depression involves dysregulation of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) signaling in the brain. While this model is an oversimplification, reduced serotonergic and noradrenergic transmission in limbic and cortical circuits is well documented in depressed individuals [2]. More recent research implicates glutamate, GABA, and neuroinflammatory pathways as well.
### 2. Genetic Predisposition
Twin studies suggest that the heritability of MDD is approximately 30–40%. Having a first-degree relative with depression roughly doubles or triples one's lifetime risk. No single gene accounts for this risk; rather, depression appears to be polygenic, with many gene variants of small effect interacting with environmental factors [2].
### 3. Psychosocial Stressors
Adverse life events — including bereavement, relationship breakdown, financial hardship, job loss, chronic illness, and trauma — are among the most potent precipitants of depressive episodes. Childhood adversity (neglect, abuse, parental loss) is particularly associated with recurrent and treatment-resistant depression in adulthood.
### 4. Chronic Medical Illness
Depression commonly co-occurs with chronic conditions such as cardiovascular disease, diabetes, cancer, chronic pain syndromes, hypothyroidism, and neurological disorders (stroke, Parkinson's disease, multiple sclerosis). In these cases, biological mechanisms (inflammation, HPA axis dysregulation) and psychosocial burden both contribute.
### 5. Hormonal Changes
Fluctuations in reproductive hormones may trigger depressive episodes in susceptible individuals. This is seen in premenstrual dysphoric disorder (PMDD), perinatal depression (affecting up to 15–20% of birthing parents), and perimenopausal mood disturbances.
### 6. Substance Use
Alcohol, cannabis, opioids, benzodiazepines, and stimulant withdrawal can all produce or worsen depressive symptoms. Chronic alcohol misuse in particular has a bidirectional relationship with depression.
### 7. Medication Side Effects
Certain prescribed medications are associated with depressive symptoms, including beta-blockers, corticosteroids, interferons, isotretinoin, some hormonal contraceptives, and certain anticonvulsants. A thorough medication review is an essential part of any depression evaluation.
### 8. Seasonal and Circadian Factors
Seasonal affective disorder (SAD), a subtype of MDD, follows a seasonal pattern — most commonly with episodes beginning in autumn or winter when daylight exposure is reduced. Disruption of circadian rhythms (e.g., shift work, jet lag) may also contribute.
---
## RED FLAGS
The following signs and symptoms associated with depression warrant **immediate medical attention** — contact emergency services (call 911 or your local emergency number), go to the nearest emergency department, or call the **988 Suicide and Crisis Lifeline** (call or text 988 in the U.S.):
- **Active suicidal ideation** — expressing a specific plan to end one's life or stating intent to die
- **Suicide attempt or self-harm** — any act of deliberate self-injury, including overdose, cutting, or other methods
- **Access to lethal means** combined with expressed hopelessness or suicidal thoughts (e.g., firearms, stockpiled medications)
- **Psychotic features** — hallucinations (hearing voices commanding self-harm) or delusions (believing one is already dead, deserves punishment)
- **Severe psychomotor retardation** — inability to eat, drink, move, or communicate (depressive stupor)
- **Acute substance intoxication or withdrawal** combined with suicidal statements
- **Abrupt behavioral changes** — suddenly giving away possessions, writing farewell notes, or expressing that others "would be better off" without them
- **Catatonia** — unresponsiveness, rigidity, or bizarre posturing in the context of severe depression
- **Homicidal ideation** — thoughts of harming others, particularly in the context of delusional depression
> **Crisis resources:** In the U.S., call or text **988** (Suicide and Crisis Lifeline). In the UK, call **116 123** (Samaritans). In the EU, call **112** for emergency services.
---
## Self-Care at Home
Non-pharmacological self-care strategies are supported by evidence and may be appropriate for mild-to-moderate depression, either as standalone measures or as adjuncts to professional treatment. They should not replace professional care for moderate-to-severe depression.
### Physical Activity
Exercise is one of the most well-evidenced non-pharmacological interventions for depression. A Cochrane systematic review found that exercise has a moderate-to-large positive effect on depressive symptoms compared with no treatment or control interventions [4]. Current evidence supports:
- **Aerobic exercise** (e.g., brisk walking, jogging, cycling) — 150 minutes per week at moderate intensity
- **Resistance training** — also shown to reduce depressive symptoms
- Even modest amounts of activity (e.g., 30 minutes of walking, 3 times per week) may provide benefit
### Sleep Hygiene
Sleep disturbance is both a symptom and a perpetuating factor in depression. Evidence-based sleep hygiene strategies include:
- Maintaining a consistent wake time and bedtime
- Limiting screen exposure (blue light) 1–2 hours before bed
- Keeping the bedroom cool, dark, and quiet
- Avoiding caffeine after midday and alcohol before bed
- Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended by NICE for comorbid insomnia and depression
### Social Connection
Social isolation strongly predicts worse depression outcomes. Even small steps — reaching out to a friend, attending a support group, or engaging in community activities — may buffer against depressive episodes.
### Structured Routine and Behavioral Activation
Behavioral activation — scheduling pleasurable and meaningful activities — is an evidence-based psychological strategy for depression. Maintaining regular daily routines (meals, exercise, wake/sleep times) provides structure that counteracts the withdrawal and inertia common in depression.
### Stress Reduction
- **Mindfulness-based cognitive therapy (MBCT)** is recommended by NICE for prevention of relapse in recurrent depression [7]
- Relaxation techniques, yoga, and tai chi have modest evidence for reducing depressive symptoms
- Limiting exposure to distressing news and social media content may help
### Nutrition
While no specific "anti-depression diet" is proven, the Mediterranean diet pattern — rich in vegetables, fruits, whole grains, fish, and olive oil — has been associated with lower depression risk in observational studies. Avoiding excessive alcohol and processed foods is generally advisable.
### Light Therapy
For seasonal affective disorder (SAD), bright light therapy (10,000 lux, 20–30 minutes in the morning) is a first-line treatment with good evidence of efficacy.
---
## OTC Medications That May Help
Over-the-counter options for depression are limited. Most effective antidepressant medications require a prescription. The following supplements have some evidence but should be discussed with a healthcare provider, especially due to potential drug interactions.
| Class | Example | Typical Adult Dose | Notes |
|---|---|---|---|
| Herbal (Hypericum) | St. John's Wort (*Hypericum perforatum*) | 300 mg (standardized to 0.3% hypericin) three times daily | Effective for mild-to-moderate depression in a Cochrane review [6]. **Major drug interactions**: reduces efficacy of oral contraceptives, warfarin, SSRIs (risk of serotonin syndrome), HIV antiretrovirals, cyclosporine, and many others. Not suitable for severe depression. Not FDA-approved for depression. |
| Omega-3 Fatty Acids | EPA/DHA fish oil supplements | 1–2 g EPA per day | Modest evidence as adjunct to antidepressants. EPA appears more effective than DHA for mood. Generally well tolerated; may increase bleeding risk with anticoagulants. |
| Amino Acid Precursor | SAMe (S-adenosyl-L-methionine) | 400–1600 mg/day | Some evidence for mild-to-moderate depression. May cause GI upset, anxiety, or insomnia. Risk of serotonin syndrome if combined with serotonergic medications. Avoid in bipolar disorder (may trigger mania). |
| Vitamin | Vitamin D3 (cholecalciferol) | 1000–2000 IU/day | May help if vitamin D deficiency is confirmed. Evidence for depression benefit in non-deficient individuals is weak. Check serum 25(OH)D levels first (see [Lab Tests](/tests/vitamin-d)). |
| B Vitamins | Folate / L-methylfolate | Folate 400–800 mcg/day; L-methylfolate 15 mg/day (prescription in some formulations) | Low folate levels are associated with poorer antidepressant response. L-methylfolate 15 mg/day has been studied as an SSRI augmentation strategy. |
> **Important:** St. John's Wort is the most studied OTC option, but its extensive drug interactions make it unsuitable for many patients. Always inform your healthcare provider if you are taking any supplement, as interactions with prescription antidepressants can be dangerous.
---
## Prescription Options
Prescription antidepressants are generally recommended for **moderate-to-severe depression** and may be appropriate for mild depression when psychotherapy alone has not been effective. A landmark 2018 network meta-analysis of 21 antidepressants in over 116,000 participants confirmed that all studied antidepressants were more effective than placebo for acute MDD [3].
Antidepressants are typically prescribed by **primary care physicians, psychiatrists, nurse practitioners, and physician assistants**. Complex or treatment-resistant cases generally warrant psychiatric referral.
### First-Line Medications
| Class | Examples | Typical Adult Starting Dose | Notes |
|---|---|---|---|
| SSRIs (Selective Serotonin Reuptake Inhibitors) | Sertraline, escitalopram, fluoxetine, citalopram, paroxetine | Sertraline 50 mg/day; Escitalopram 10 mg/day | Generally first-line due to favorable side-effect profile. Common side effects: GI upset, sexual dysfunction, insomnia or drowsiness. Escitalopram and sertraline ranked favorably for efficacy and tolerability [3]. |
| SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) | Venlafaxine, duloxetine, desvenlafaxine | Venlafaxine 75 mg/day; Duloxetine 60 mg/day | Useful when comorbid pain is present (duloxetine). May raise blood pressure at higher doses (venlafaxine). Discontinuation syndrome can be significant. |
| Atypical Antidepressants | Bupropion, mirtazapine | Bupropion 150 mg/day; Mirtazapine 15 mg/day | Bupropion: no sexual side effects, may aid smoking cessation; contraindicated in seizure disorders and eating disorders. Mirtazapine: sedating, may increase appetite/weight — useful in underweight or insomnia-predominant depression. |
### Second-Line and Augmentation Options
| Class | Examples | Notes |
|---|---|---|
| Tricyclic Antidepressants (TCAs) | Amitriptyline, nortriptyline, imipramine | Effective but more side effects (anticholinergic, cardiac). Dangerous in overdose. Require ECG monitoring. |
| MAOIs (Monoamine Oxidase Inhibitors) | Phenelzine, tranylcypromine | Reserved for treatment-resistant cases. Strict dietary restrictions (tyramine). Significant drug interactions. |
| Atypical Antipsychotics (augmentation) | Aripiprazole, quetiapine, brexpiprazole | FDA-approved as adjuncts to antidepressants for treatment-resistant MDD. Metabolic side effects require monitoring. |
| NMDA Receptor Modulators | Esketamine (Spravato® nasal spray) | FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation. Administered under medical supervision (REMS program). |
### Key Prescribing Principles
- **Onset of action:** Most antidepressants require 2–4 weeks for initial response and 6–8 weeks for full effect [5]
- **Duration of treatment:** Generally at least 6–12 months after remission for a first episode; longer for recurrent depression
- **Black Box Warning:** FDA mandates a warning about increased risk of suicidal thoughts and behavior in children, adolescents, and young adults (under 25) during early treatment. Close monitoring is essential during the first weeks.
- **Discontinuation:** Antidepressants should generally be tapered gradually to avoid discontinuation syndrome — never stopped abruptly without medical guidance
### Psychotherapy
Psychotherapy is a first-line treatment for depression, either alone (mild-to-moderate) or combined with medication (moderate-to-severe):
- **Cognitive Behavioral Therapy (CBT)** — strongest evidence base
- **Interpersonal Therapy (IPT)** — well-evidenced, focuses on relationship difficulties
- **Behavioral Activation (BA)** — effective and may be simpler to deliver
- **Psychodynamic Psychotherapy** — evidence for moderate benefit
NICE guidelines recommend offering a choice of CBT, BA, IPT, or short-term psychodynamic therapy for adults with depression [7].
---
## Lab Tests Typically Ordered
While there is no blood test that diagnoses depression, laboratory investigations are important to **rule out medical conditions** that mimic or contribute to depressive symptoms, and to establish a baseline before starting certain medications.
| Test | Rationale |
|---|---|
| [Thyroid function tests (TSH, free T4)](/tests/thyroid-function) | Hypothyroidism is a common and treatable cause of depressive symptoms. Should be checked in all new presentations of depression. |
| [Complete blood count (CBC)](/tests/complete-blood-count) | Anemia (especially iron-deficiency) can present with fatigue and low mood. |
| [Comprehensive metabolic panel (CMP)](/tests/metabolic-panel) | Assesses electrolytes, glucose, renal and hepatic function. Hyponatremia and hypercalcemia can cause mood changes. Hepatic function is relevant before starting certain antidepressants. |
| [Vitamin D (25-hydroxyvitamin D)](/tests/vitamin-d) | Vitamin D deficiency is associated with depression and is correctable. |
| [Vitamin B12 and folate](/tests/vitamin-b12) | Deficiency can cause or worsen depressive symptoms and may impair response to antidepressants. |
| [HbA1c or fasting glucose](/tests/hba1c) | Depression and diabetes frequently co-occur. Screening is warranted, particularly given metabolic side effects of some psychotropic medications. |
| [Iron studies (ferritin, serum iron, TIBC)](/tests/iron-studies) | Iron deficiency — even without frank anemia — may contribute to fatigue and cognitive symptoms. |
| Urine drug screen | When substance use is suspected as a contributing or complicating factor. |
| Testosterone (in males) | Low testosterone may present with depressive symptoms, fatigue, and low libido in men. |
| Cortisol (AM cortisol or dexamethasone suppression test) | If Cushing's syndrome is suspected (weight gain, striae, hypertension with mood disturbance). |
---
## Special Populations
### Children and Adolescents
- Depression in children may present differently than in adults — irritability is often more prominent than sadness
- **Fluoxetine** is FDA-approved for MDD in children aged 8 and older; **escitalopram** is approved for ages 12 and older
- The FDA Black Box Warning regarding suicidality in under-25s applies to all antidepressants — close monitoring (weekly initially) is essential
- Psychotherapy (especially CBT and IPT) is generally recommended as a first-line treatment for mild-to-moderate depression in young people
- **Pediatric dosing should only be determined by a qualified prescriber** — doses differ from adult doses and require careful titration
- St. John's Wort and other OTC supplements have not been adequately studied in pediatric populations and should generally be avoided
### Pregnancy and Postpartum
- Depression affects an estimated 10–20% of pregnant and postpartum individuals
- Untreated depression in pregnancy carries risks: preterm birth, low birth weight, impaired maternal-infant bonding, and postpartum depression
- **SSRIs** are among the most studied antidepressants in pregnancy. Sertraline and escitalopram are generally considered to have favorable risk-benefit profiles. Paroxetine has been associated with a small increased risk of cardiac malformations and is generally avoided in the first trimester
- **Brexanolone** (Zulresso®) is FDA-approved specifically for postpartum depression (administered as a 60-hour IV infusion under medical supervision)
- **Psychotherapy** (particularly CBT and IPT) is recommended as a first-line option, especially for mild-to-moderate perinatal depression
- All treatment decisions in pregnancy should involve a shared decision-making process between the patient, obstetrician, and mental health provider, weighing individual risks and benefits
- **St. John's Wort is contraindicated** during pregnancy due to insufficient safety data and potential interactions
### Elderly
- Depression in older adults is common but frequently underdiagnosed — symptoms may overlap with cognitive decline, grief, or medical comorbidities
- Somatic complaints (pain, fatigue, GI symptoms) may be more prominent than mood complaints ("depression without sadness")
- **Pharmacokinetic changes** in older adults (reduced hepatic and renal clearance) necessitate lower starting doses — the principle of "start low, go slow" applies
- **SSRIs** (particularly sertraline and escitalopram) are generally preferred. Citalopram has a dose ceiling of 20 mg/day in patients over 60 due to QT prolongation risk (FDA safety communication)
- **TCAs** should generally be avoided in the elderly due to anticholinergic effects (confusion, urinary retention, constipation, falls) and cardiac risk
- **Hyponatremia** (SIADH) is more common with SSRIs in older adults — sodium levels should be monitored
- Depression in the elderly is a significant risk factor for suicide, particularly in older men — suicidal ideation should always be assessed
### Athletes
- Athletes are not immune to depression — prevalence estimates range from 4% to 34% depending on the sport, level, and assessment method
- Unique risk factors include overtraining syndrome, injury, career transitions, performance pressure, concussion history, and body image concerns
- Exercise, while generally antidepressant, can become harmful in the context of overtraining — rest and recovery should be emphasized
- **Medication considerations for competitive athletes:** Some antidepressant side effects (weight gain, sedation, tremor) may affect performance. Bupropion may be preferred in some cases due to its activating profile and absence of sexual side effects and weight gain
- Athletes subject to anti-doping regulations should note that most antidepressants are **not prohibited** by the World Anti-Doping Agency (WADA), but individual governing bodies may have specific rules — verification through WADA's prohibited list or a team physician is advisable
---
## When to Escalate
Knowing when to seek professional help — and at what urgency level — is critical in managing depression.
### Schedule a GP / Primary Care Appointment (Within Days)
- Depressed mood or loss of interest lasting **two weeks or more**
- Sleep, appetite, or energy changes that affect daily functioning
- Difficulty performing at work, school, or in relationships
- First episode of depression or return of previously treated symptoms
- Interest in discussing medication or therapy options
- Physical symptoms that may point to an underlying medical cause (fatigue, weight change, cognitive slowing)
### Same-Day or Urgent Care Appointment
- Rapid worsening of symptoms despite ongoing treatment
- New or worsening side effects from antidepressant medication (e.g., agitation, worsening anxiety, emerging suicidal thoughts)
- **Passive suicidal ideation** — thoughts such as "I wish I were dead" or "I wouldn't mind not waking up" without a specific plan
- Inability to care for oneself (not eating, not drinking, unable to get out of bed for extended periods)
- Significant functional impairment (unable to work, care for dependents)
- Concurrent substance misuse that is escalating
### Emergency Department / Call 911 (Immediately)
- **Active suicidal ideation with plan or intent**
- **Suicide attempt** or act of deliberate self-harm
- **Psychotic symptoms** — hallucinations, delusions, disorganized thinking
- **Catatonic features** — unresponsiveness, immobility, refusal to eat or drink
- **Homicidal ideation** — thoughts of harming others
- Severe medication reaction (e.g., serotonin syndrome: agitation, hyperthermia, clonus, rigidity)
> **Remember:** If you or someone you know is in crisis, contact the **988 Suicide and Crisis Lifeline** (call or text 988 in the U.S.) or go to the nearest emergency department. You do not need to face depression alone.
---
## References
[1] GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry*. 2022;9(2):137-150. PMID:35026139.
[2] Malhi GS, Mann JJ. Depression. *Lancet*. 2018;392(10161):2299-2312. PMID:30396512.
[3] Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*. 2018;391(10128):1357-1366. PMID:29477251.
[4] Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. *Cochrane Database Syst Rev*. 2013;(9):CD004366. PMID:24026850.
[5] Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 1. Disease burden and principles of care. *Can J Psychiatry*. 2016;61(9):510-523. PMID:27486148.
[6] Linde K, Berner MM, Kriston L. St John's wort for major depression. *Cochrane Database Syst Rev*. 2008;(4):CD000448. PMID:18843608.
[7] National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. Published June 2022. Available at: https://www.nice.org.uk/guidance/ng222.
[8] Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. *JAMA*. 2010;303(1):47-53. PMID:20051569.
---
*This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment of depression or any medical condition.*
